141 related articles for article (PubMed ID: 21873969)
1. High-dose hyperfractionated accelerated radiotherapy in non-small cell lung cancer.
De Ruysscher D; Reymen B; Van Baardwijk A
Minerva Chir; 2011 Aug; 66(4):341-5. PubMed ID: 21873969
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
3. A treatment planning study evaluating a 'simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer.
Dirkx ML; van Sörnsen De Koste JR; Senan S
Lung Cancer; 2004 Jul; 45(1):57-65. PubMed ID: 15196735
[TBL] [Abstract][Full Text] [Related]
4. Programming of radiotherapy in the treatment of non-small-cell lung cancer--a way to advance care.
Saunders MI
Lancet Oncol; 2001 Jul; 2(7):401-8. PubMed ID: 11905734
[TBL] [Abstract][Full Text] [Related]
5. Altered fractionation schemes in radiotherapy.
Stuschke M; Pöttgen C
Front Radiat Ther Oncol; 2010; 42():150-156. PubMed ID: 19955801
[TBL] [Abstract][Full Text] [Related]
6. Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer.
van Baardwijk A; Reymen B; Wanders S; Borger J; Ollers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Lunde R; Peters F; Lambin P; De Ruysscher D
Eur J Cancer; 2012 Oct; 48(15):2339-46. PubMed ID: 22608261
[TBL] [Abstract][Full Text] [Related]
7. Accelerated hyperfractionated radiotherapy combined with induction and concomitant chemotherapy for inoperable non-small-cell lung cancer--impact of total treatment time.
Nyman J; Bergman B; Mercke C
Acta Oncol; 1998; 37(6):539-45. PubMed ID: 9860311
[TBL] [Abstract][Full Text] [Related]
8. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
9. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
Saunders M; Dische S; Barrett A; Harvey A; Griffiths G; Palmar M
Radiother Oncol; 1999 Aug; 52(2):137-48. PubMed ID: 10577699
[TBL] [Abstract][Full Text] [Related]
10. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
11. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
[TBL] [Abstract][Full Text] [Related]
12. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
13. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
[TBL] [Abstract][Full Text] [Related]
15. High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results.
King SC; Acker JC; Kussin PS; Marks LB; Weeks KJ; Leopold KA
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):593-9. PubMed ID: 8948343
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
17. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
19. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
20. A systematic overview of radiation therapy effects in non-small cell lung cancer.
Sirzén F; Kjellén E; Sörenson S; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):493-515. PubMed ID: 14596509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
